MMS Holdings Launches New Application

June 27, 2019
Applied Clinical Trials

MMS Holdings, a data-focused CRO, has announced the launch of Automatiqc (pronounced: automatic.) Automatiqc is a new cloud-based application that performs quality control and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

This new application is customizable, enabling users to tailor the software to client style guides including journal requirements and other established guides. Automatiqc does not require special training. Automatiqc can be used for any Microsoft Word-based document type including, but not limited to:

  • Clinical Study Reports (CSRs)

  • Protocols and Investigator’s Brochures (IB)

  • Module 2 IND and NDA submission documents (M2.5, M2.7.1, M2.7.2, M2.7.3, M2.7.4, M2.7.5, and M2.7.6)

  • Module 5 Integrated Summary of Efficacy (ISE) and Integrated Summary of Safety (ISS)

  • Health Authority Responses and Response to Queries (RTQs)

  • Safety Narratives and Risk Management Plans (RMPs)

  • Publications for peer-reviewed journals and more!

This new application is currently available for use through a service relationship with MMS or licensing of the application as software-as-a-service.

For more information, visit www.mmsholdings.com